Results 61 to 70 of about 22,836 (233)

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

First evaluation of glucose-6-phosphate dehydrogenase (G6PD) deficiency in vivax malaria endemic regions in the Republic of Korea. [PDF]

PLoS ONE, 2014
BACKGROUND: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme defect and affects more than 400 million people worldwide.
Youn-Kyoung Goo, So-Young Ji, Hyun-Il Shin, Jun-Hye Moon, Shin-Hyung Cho, Won-Ja Lee, Jung-Yeon Kim   +6 more
doaj   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

G6PD deficiency does not enhance susceptibility for acquiring Helicobacter pylori infection in Sardinian patients [PDF]

, 2016
Background: Subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be more susceptible to infections due to impaired leukocyte bactericidal activity. The disorder is common in the Mediterranean area.
Dore, Maria Pina, Marras, Giuseppina, Pes, Giovanni Mario, Rocchi, Chiara, Soro, Sara   +4 more
core   +2 more sources

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Newborn screening for G6PD deficiency in HeFei, FuYang and AnQing, China: Prevalence, cut-off value, variant spectrum [PDF]

Journal of Medical Biochemistry
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked recessive Mendelian genetic disorder characterized by neonatal jaundice and hemolytic anemia, affecting more than 400 million people worldwide.
Li Hui, Ch'ih Yah, Li Meiling, Luo Yulei, Liu Hao, Xu Junyang, Song Wangsheng, Ma Qingqing, Shao Ziyu   +8 more
doaj   +1 more source

3′-UTR variations and G6PD deficiency [PDF]

Journal of Human Genetics, 2013
The combination of two silent mutations, c.1311C>T in exon 11 and IVS11 T93C (glucose-6-phosphate dehydrogenase (G6PD) 1311T/93C), with unknown mechanism, have been reported in G6PD-deficient individuals in Asian populations including Malaysian aboriginal group, Negrito.
Farahnaz, Amini, Endom, Ismail
openaire   +2 more sources

Energy metabolism, adenosine, and glutamate signaling reprogramming by decanoic acid in Glut1 disorder syndrome

Epilepsia Open, EarlyView.
Abstract Glut1 deficiency syndrome (Glut1DS) leads to neurological and cognitive symptoms and is primarily treated using carbohydrate‐restricted ketogenic diets. However, a recent clinical trial of a less restrictive, non‐ketogenic, medium chain triglyceride (MCT) diet with a high decanoic acid content suggests efficacy in Glut1DS treatment.
Erwann Pain, Yatra Kapatel, Pankaj K. Singh, Katie Lloyd Jones, Jamuna Selvakumaran, Alberto Malerba, Walter Lucchesi, Tricia Rutherford, Christina A. Gurnett, Matthew C. Walker, Robin S. B. Williams   +10 more
wiley   +1 more source

Genotype-phenotype association and biochemical analyses of glucose-6-phosphate dehydrogenase variants: Implications for the hemolytic risk of using 8-aminoquinolines for radical cure

Frontiers in Pharmacology, 2022
Background:Plasmodium vivax remains the malaria species posing a major threat to human health worldwide owing to its relapse mechanism. Currently, the only drugs of choice for radical cure are the 8-aminoquinolines (primaquine and tafenoquine), which are
Sirapapha Sudsumrit, Kamonwan Chamchoy, Duantida Songdej, Poom Adisakwattana, Srivicha Krudsood, Emily R. Adams, Mallika Imwong, Ubolsree Leartsakulpanich, Usa Boonyuen   +8 more
doaj   +1 more source

Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine. [PDF]

, 2014
Glucose-6-phosphate dehydrogenase (G6PD) enzyme function and genotype were determined in Ugandan children with uncomplicated falciparum malaria enrolled in a primaquine trial after exclusion of severe G6PD deficiency by fluorescent spot test.
Bousema, Teun, Drakeley, Chris, Eziefula, Alice C, Grignard, Lynn, Kamya, Moses R, Kiggundu, Moses, Opus, Salome, Pett, Helmi, Staedke, Sarah G, Yeung, Shunmay   +9 more
core   +4 more sources